Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997. - Wikidata - wikimedia - TriplyDB

Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997.

Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997.

http://www.wikidata.org/entity/Q30804635

about

Antimicrobial Resistance and Reduced Susceptibility in Clostridium difficile: Potential Consequences for Induction, Treatment, and Recurrence of C. difficile Infection The changing epidemiology of Clostridium difficile infections Clostridium difficile brain empyema after prolonged intestinal carriage.Surveillance of Antibiotic Resistance among Hospital- and Community-Acquired Toxigenic Clostridium difficile Isolates over 5-Year Period in Kuwait.The ecology and pathobiology of Clostridium difficile infections: an interdisciplinary challenge Characterization of Clostridium difficile strains isolated from patients in Ontario, Canada, from 2004 to 2006 Proteomic analysis of a NAP1 Clostridium difficile clinical isolate resistant to metronidazole.Development of pseudomembranous colitis four months after initiation of rifampicin.gyrA and gyrB mutations are implicated in cross-resistance to Ciprofloxacin and moxifloxacin in Clostridium difficile.Frequent emergence of resistance in Clostridium difficile during treatment of C. difficile-associated diarrhea with fusidic acid.Rifampin-induced Pseudomembranous Colitis with Rectosigmoid Sparing.Antimicrobial susceptibility pattern of Clostridium difficile and its relation to PCR ribotypes in a Swedish university hospital A case of pseudomembranous colitis associated with rifampin.Metronidazole resistance in Clostridium difficile is heterogeneous.

P2860

Q28084026-E276D96F-5497-40E4-9105-A0CFA2AAE40C Q28750385-2E4FA24F-1467-4BD6-965D-B7E587485C62 Q34748612-82A91E47-FAFA-45E4-99E1-0BEF44C07572 Q36106735-53602EB9-A61F-45FB-958C-3C4D7A27485C Q36889259-E5666D8C-C9C2-42F1-81B1-1C0FFF21C9A6 Q36898358-56723359-BE24-476F-AC64-39AAA0EE5FDD Q37439161-7E90F837-0584-468E-BA03-2C773F124795 Q38477038-9870E57B-2964-42C3-9DBD-79414B2BA767 Q39657922-A648C8CB-416C-4CC1-AF37-EF8A45A16528 Q41833887-55DC6320-4B76-4485-A085-2DCFA1CC272B Q42015365-36AEBD94-7B0A-4C64-ADC9-53941B2780EF Q42424817-CFCF9DB7-B7B2-4C51-834C-56E0B545123B Q42430695-EF58F0A1-A663-4530-93C3-231C3D08D644 Q42752873-BFA84EC4-32E8-4A53-AC2D-B9C4AB97EC74

P2860

Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997.

http://www.wikidata.org/entity/Q30804635

description

1999 nî lūn-bûn

@nan

1999 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

1999 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

1999年の論文

@ja

1999年論文

@yue

1999年論文

@zh-hant

1999年論文

@zh-hk

1999年論文

@zh-mo

1999年論文

@zh-tw

1999年论文

@wuu

name

Antimicrobial susceptibilities ...... ed in France in 1991 and 1997.

@ast

Antimicrobial susceptibilities ...... ed in France in 1991 and 1997.

@en

type

label

Antimicrobial susceptibilities ...... ed in France in 1991 and 1997.

@ast

Antimicrobial susceptibilities ...... ed in France in 1991 and 1997.

@en

prefLabel

Antimicrobial susceptibilities ...... ed in France in 1991 and 1997.

@ast

Antimicrobial susceptibilities ...... ed in France in 1991 and 1997.

@en

P1433

Q30804635-C6140804-92FB-48AA-848D-68F59005D6A5

P1476

Q30804635-C1DCCBB3-0D1F-4062-8F48-80061569A9CF

P2093

Q30804635-1D9632AA-D07D-4D87-AB0F-172B83E3D8D5

Q30804635-25C4578F-7D56-476D-99B5-1ABB0DE3078E

Q30804635-25CF4F8D-662F-4858-9667-BD42068EBBB0

Q30804635-34DB8671-C99C-4D55-9E08-A6AD1AD7F8D9

Q30804635-3AAD1E0D-4459-4462-AECC-F959941AB799

Q30804635-437E78CA-64DF-475E-B128-31A07A5B6DB4

Q30804635-76DBEB64-7670-46CF-93BF-ACEDE13C59B5

Q30804635-883A51A6-4979-45CF-8B51-A309B3E4DCF3

Q30804635-CDC320D2-C3ED-4A6B-8058-8997F796B069

Q30804635-E6ED6208-817B-464C-83E8-2F5C27A98765

P2860

Q30804635-030D85E9-BF7D-4183-9D04-AD4D13D034E6

Q30804635-0AD6F2EB-D14A-4F55-ADB7-B9BDECD4D8FE

Q30804635-194F23AF-2C90-446F-81F1-97D1E153AB36

Q30804635-293389A1-E7B4-45B5-BA4F-0178F98B80BE

Q30804635-2BEE4511-0A83-422D-97F3-A3B29D8C4FA2

Q30804635-2C6C3E0A-B2CA-4EAF-8FB2-B536784262B0

Q30804635-40C9E687-6D78-480F-887B-B1D46AD1299B

Q30804635-454F07C1-8C59-4419-98AD-C59BEA17F5E9

Q30804635-4901BC94-FE9D-46BE-B6F9-A5FEF138F903

Q30804635-4AA0A46D-4D40-4A97-A05A-751DC39AF42B

P304

Q30804635-CED78E2B-1359-4EB0-AE5E-C7F8A22A4639

P31

Q30804635-D4DEFA0A-E56D-4434-80FB-E711B0170EB1

P407

Q30804635-717FEF56-E31C-40F2-9B47-D4CC8B8EC138

P433

Q30804635-9BC40B38-AF1C-4013-9091-5B17A4ED129D

P478

Q30804635-FCDCDFEE-008E-44EF-A20F-F215345EE59E

P577

Q30804635-A378DF04-674D-443E-A96B-E4DA272A350C

P698

Q30804635-CB4E2253-02BE-4F55-9B04-4B9AD6FDB610

P921

Q30804635-E36E5974-D6D2-4B15-8B9A-3AC377E4D022

P932

Q30804635-DE828FBA-E3E9-438E-8CB6-4A84A5CC5E38

P1433

Antimicrobial Agents and Chemotherapy

P1476

Antimicrobial susceptibilities ...... ed in France in 1991 and 1997.

@en

P2093

B Burghoffer

http://www.w3.org/2001/XMLSchema#string

C Coudert

http://www.w3.org/2001/XMLSchema#string

D Decré

http://www.w3.org/2001/XMLSchema#string

D Lesage

http://www.w3.org/2001/XMLSchema#string

F Barbut

http://www.w3.org/2001/XMLSchema#string

F Delisle

http://www.w3.org/2001/XMLSchema#string

J C Petit

http://www.w3.org/2001/XMLSchema#string

M Delmée

http://www.w3.org/2001/XMLSchema#string

N Sano

http://www.w3.org/2001/XMLSchema#string

V Avesani

http://www.w3.org/2001/XMLSchema#string

P2860

Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection.

Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis.

Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea.

Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile.

Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia.

In vitro activities of ramoplanin and four glycopeptide antibiotics against clinical isolates of Clostridium difficile

Evaluation of the E test for susceptibility testing of anaerobic bacteria.

Correlation between serogroup and susceptibility to chloramphenicol, clindamycin, erythromycin, rifampicin and tetracycline among 308 isolates of Clostridium difficile.

P304

2607-2611

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

43

http://www.w3.org/2001/XMLSchema#string

P577

1999-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

10543736

http://www.w3.org/2001/XMLSchema#string

P921

Clostridium difficile

P932

89532

http://www.w3.org/2001/XMLSchema#string